Abbott: The Global Fight Begins Here

For Mary Rodgers, an Abbott senior scientist who spends her work life hunting viruses as part of the company's diagnostics business, it's her calling to do her part to keep the world's blood supply safe.

Who are the Virus Hunters? It's a fun way to describe a serious job. These are our scientists who work to identify, catalog, track and test mutating strains of HIV, hepatitis viruses, and other bugs.

For Mary Rodgers, an Abbott (No. 10 on the DiversityInc Top 50 Companies list) senior scientist who spends her work life hunting viruses as part of the company's diagnostics business, it's her calling to do her part to keep the world's blood supply safe.

She does that as a member of Abbott's Global Surveillance Program, built on a one-of-a-kind collection of HIV and hepatitis virus strains from around the world. It includes more than 60,000 samples collected over 20 years from 40 countries on six continents. If a new strain is discovered, our scientists make sure that our blood screening and diagnostic tests can detect it. And this is important, considering that Abbott tests are used to screen more than half of the world's blood supply.

That program in turn helps further the capabilities of many of Abbott's diagnostics tools. Because if a virus can't be found in testing, it can't be treated. That's how outbreaks happen.

"It's not easy to tackle new viral threats as they occur in real-time," said John R. Hackett, Jr., Ph.D., divisional vice president, Applied Research and Technology, for Abbott's diagnostics business. "With diagnostics and ongoing vigilance, we're getting better at rapidly identifying the cause of these outbreaks, which could lead to quicker response and better treatment."

The battle is constant. Viruses are always evolving. It's their fight for survival as much as humanity's.

"We need to stay on top of current epidemics like HIV, HCV, HBV. And part of what's involved in that is understanding (genetic) sequences, because as these viruses evolve, the means of detecting them has to keep pace," said Michael Berg, an Abbott senior scientist who works on the new virus discovery program and with Rodgers and Hackett on the global surveillance program.

Abbott's Diagnostic portfolio is a leader in the industry, in part because of the range of accurate tests our devices have the capability to execute. Our instruments and tests screen more of the world's blood than any other company.

Because, as Hackett rightly points out, "How far do we go to ensure that there is a safe blood supply? I'm always sitting there thinking, 'You never know. You never know who's going to need it.'"

We're doing our part to accurately, precisely track and test for these deadly viruses, to speed treatment development and patient care.

The global fight starts here. We are The Virus Hunters.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.